Vorsetuzumab mafodotin
Modify Date: 2024-04-08 00:18:52
Vorsetuzumab mafodotin structure
|
Common Name | Vorsetuzumab mafodotin | ||
|---|---|---|---|---|
| CAS Number | 1165741-01-4 | Molecular Weight | 150 (kDa) | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Vorsetuzumab mafodotinVorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1]. |
| Name | Vorsetuzumab mafodotin |
|---|
| Description | Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Vorsetuzumab mafodotin (SGN-75; 0.01-10000 ng/mL; for 96 h) induces dose-dependent cytotoxicity that is specific with an IC50 of 29 ng/mL[1]. Cell Cytotoxicity Assay[1] Cell Line: SK-OV-3 cells Concentration: 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL Incubation Time: 96 h Result: Induced dose-dependent cytotoxicity. |
| In Vivo | Vorsetuzumab mafodotin (SGN-75; 3 mg/kg; four intraperitoneal injections at 4-day interval) significantly reduces median tumour volumes and delays tumour growth[1]. Animal Model: Nude (nu/nu) female mice injected with MiaPaCa-2/CD70 tumour pieces[1] Dosage: 3 mg/kg Administration: Intraperitoneal injection; every 4 days; for a total of four doses Result: Significantly reduced median tumour volumes and delayed tumour growth. |
| References |
| Molecular Weight | 150 (kDa) |
|---|